FLT3 and acute myeloid leukemia: Overall, these data obtained from primary FLT3-ITD+ AML patient samples further substantiate that the combination of p300/CBP inhibitors and FLT3 inhibitors concomitantly suppresses both FLT3 signaling and H3K27Ac, demonstrating synergistic antileukemia effects and highlighting considerable promise for the clinical application of such combination therapies.